Chronic hepatitis С and non-alcoholic fatty liver disease. Main aspects of pathogenesis


Cite item

Full Text

Abstract

The main pathogenetic aspects of non-alcoholic fatty liver disease as a comorbid factor of chronic hepatitis C are considered. Non-alcoholic fatty liver disease is currently the most common liver disease worldwide, both among adults and children. It is usually accompanied by obesity, insulin resistance and diabetes mellitus. Non-alcoholic fatty liver disease includes a spectrum of pathologies from simple fatty liver infiltration to non-alcoholic steatohepatitis, which is characterized by inflammation with potential progression to fibrosis and cirrhosis over time. On average, non-alcoholic fatty liver disease occurs in 55% of patients with chronic hepatitis C, which is significantly higher than the prevalence of each disease individually. This condition leads to a greater rate of progression of fibrosis, as well as a continuing high risk of developing cirrhosis and hepatocellular carcinoma even after achieving a sustained virological response. In this regard, complex therapy aimed at normalization of the nutritional status, optimization of body weight, correction of impaired intestinal microflora, reduction of severity of liver steatosis and achieving a sustained virological response is a priority task in the treatment of patients with chronic hepatitis C.

About the authors

K V Zhdanov

Военно-медицинская академия им. С.М. Кирова

Email: vmed-2007@yandex.ru
Санкт-Петербург

S S Karyakin

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

K V Kozlov

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

D A Gusev

Центр по профилактике и борьбе со СПИДом и инфекционными заболеваниями

Санкт-Петербург

V S Sukachev

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

A V Saulevich

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

M V Yaremenko

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

S N Kizhlo

Центр по профилактике и борьбе со СПИДом и инфекционными заболеваниями

Санкт-Петербург

D M Shahmanov

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

D Yu Lobzin

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

M V Kurtukov

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

M A Dzheriev

Военно-медицинская академия им. С.М. Кирова

Санкт-Петербург

References

  1. Жданов, К.В. Гепатит С и неалкогольная жировая болезнь печени у пациентов с ВИЧ-инфекцией / К.В. Жданов, К.В. Козлов, В.С. Сукачев // ВИЧ-инфекция и иммуносупрессии. - 2017. - № 1 (9). - С. 36-42.
  2. Жданов, К.В. Вирусные гепатиты / К.В. Жданов [и др.] - СПб.: Фолиант, 2011. - 304 c.
  3. Жданов, К.В. Водородный дыхательный тест в комплексной диагностике хронических вирусных гепатитов В и С / К.В. Жданов [и др.] // Лечение и профилактика. - 2014. - № 4 (12). - С. 18-26.
  4. Новикова, В.П. Неалкогольная жировая болезнь у детей: учеб- ное пособие для врачей. - СПб.: Информ-Мед, 2013. - 148 c.
  5. Сукачев, В.С. Оценка морфофункционального состояния тонкой кишки у больных хроническим гепатитом С: дис.. канд. мед. наук / В.С. Сукачев. - СПб.: ВМА, 2012. - 106 с.
  6. Abenavoli, L. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 / L. Abenavoli [et al.] // World Journal of Gastroenterology. - 2014. - № 41 (20). - P. 15233-15240.
  7. Adinolfi, L.E. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations / L.E. Adinolfi [et al.] // International Journal of Molecular Sciences. - 2016. - № 6 (17). - P. 803.
  8. Caligiuri, A. Molecular pathogenesis of NASH / A. Caligiuri, A. Gentilini, F. Marra // International Journal of Molecular Sciences. - 2016. - № 9 (17). - P. 1575.
  9. Csak, T. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis / T. Csak [et al.] // Liver Int. - 2014. - № 34. - P. 1402-1413.
  10. Day, C.P. Steatohepatitis: A tale of two «hits»? / C.P. Day, O.F. James. // Gastroenterology. - 1998. - № 114. - P. 842-845.
  11. Ding, S. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse / S. Ding [et al.] // PLoS One. - 2010. - № 5 (8). - P. 12191.
  12. Dixon, L.J. Caspase-1 as a central regulator of high fat diet- induced non-alcoholic steatohepatitis / L.J. Dixon [et al.] // PLoS One. - 2013. - № 8. - P. 56100.
  13. Douhara, A. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model / A. Douhara [et al.] // Mol. Med. Rep. - 2015. - № 11. - P. 1693-1700.
  14. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J. Hepatol. - 2016. - № 64. - P. 1388-1402.
  15. Fukui, H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia / H. Fukui // World J. Hepatol. - 2015. - № 7. - P. 425-442.
  16. Ganz, M. Immune and inflammatory pathways in NASH / M. Ganz, G. Szabo // Hepatol. Int. - 2013. - № 7. - P. 771-781.
  17. Ganz, M. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice / M. Ganz [et al.] // J. Transl. Med. - 2015. - № 13. - P. 193.
  18. Gentile, C.L. The role of fatty acids in the development and progression of non-alcoholic fatty liver disease / C.L. Gentile, M.J. Pagliassotti // J. Nutr. Biochem. - 2008. - № 19. - P. 567-576.
  19. Henao-Mejia, J. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity / J. Henao-Mejia [et al.] // Nature. - 2012. - № 482. - P. 179-185.
  20. Huebener, P. The HMGB1/RAGE axis triggers neutrophil- mediated injury amplification following necrosis / P. Huebener [et al.] // J. Clin. Investig. - 2015. - № 125. - С. 539-550.
  21. Ivanov, A.V. HCV and oxidative stress in the liver / A.V. Ivanov [et al.] // Viruses. - 2013. - № 5. - P. 439-469.
  22. Kapoor, A. Endoplasmic reticulum stress and the unfolded protein response / A. Kapoor, A.J. Sanyal // Clin. Liver Dis. - 2009. - № 13. - P. 581-590.
  23. Kirpich, I.A. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease / I.A. Kirpich, L.S. Marsano, C.J. McClain. // Clinical Biochemistry. - 2015. - № 13 - 14 (48). - P. 923-930.
  24. Liang, T.J. Pathogenesis, natural history, treatment, and prevention of hepatitis / T.J. Liang [et al.] // Am J Gastroenterol. - 2005. - № 100. - P. 1091-1098.
  25. Mehta, S. H. Hepatitis C virus infection and incident type 2 diabetes / S.H. Mehta [et al] // Hepatology. - 2003. - № 38. - P. 50-56.
  26. Minemura, M. Gut microbiota and liver diseases / M. Minemura [et al.] // World J. Gastroenterol. - 2015. - № 21. - P. 1691-1702.
  27. Miura, K. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1 in mice / K. Miura [et al.] // Gastroenterology. - 2010. - № 139. - P. 323-334.
  28. Patel, A. Hepatitis C virus infection and nonalcoholic steatohepatitis / A. Patel, S.A. Harrison // Gastroenterology & Hepatology. - 2012. - № 5 (8). - P. 305-312. 220
  29. Prawitt, J. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity / J. Prawitt [et al.] // Diabetes. - 2011. - № 60. - P. 1861-1871.
  30. Raman, M. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease / M. Raman [et al.] // Clin. Gastroenterol. Hepatol. - 2013. - № 11. - P. 868-875
  31. Sabile, A. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates / A. Sabile [et al.] // Hepatology. - 1999. - № 30. - P. 1064-1076.
  32. Shaheen, M. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the third national health and nutrition examination survey [NHANES III] / M. Shaheen [et al.] // Diabetes Res Clin Pract. - 2007. № 75. - P. 320-326.
  33. Shi, S.T. Hepatitis C virus NS5A co-localizes with the core protein on lipid droplets and interacts with apolipoproteins / S.T. Shi [et al.] // Virology. - 2002. - № 292. - P. 198-210.
  34. Shimada, K. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis / K. Shimada [et al.] // Immunity. - 2012. - № 36. - P. 401-414.
  35. Spencer, M.D. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency / M.D. Spencer [et al.] // Gastroenterology. - 2011. - № 140. - P. 976-986.
  36. Szabo, G. Inflammasomes in liver diseases / G. Szabo, T. Csak // J. Hepatol. - 2012. - № 57. - P. 642-654.
  37. Tremaroli, V. Functional interactions between the gut microbiota and host metabolism / V. Tremaroli, F. Backhed // Nature. - 2012. - № 489. - P. 242-249.
  38. Vandanmagsar, B. The NLRP3 inflammasome instigates obesity- induced inflammation and insulin resistance / B. Vandanmagsar [et al.] // Nat. Med. - 2011. - № 17. - P. 179-188.
  39. Waris, G. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress / G. Waris [et al.] // J Virol. - 2007. - № 81. - P. 8122-8130.
  40. Williams, C.D. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study / C.D. Williams [et al.] // Gastroenterology. - 2011. - № 140. - P. 124-131.
  41. Wree, A. NLRP3 inflammasome activation is required for fibrosis development in NAFLD / A. Wree [et al.] // J. Mol. Med. - 2014. - № 92. - P. 1069-1082.

Copyright (c) 2018 Zhdanov K.V., Karyakin S.S., Kozlov K.V., Gusev D.A., Sukachev V.S., Saulevich A.V., Yaremenko M.V., Kizhlo S.N., Shahmanov D.M., Lobzin D.Y., Kurtukov M.V., Dzheriev M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies